Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06753006Not ApplicableRecruiting

Research on the Effectiveness of Neurorehabilitation After Stroke

Role: collaborator

NCT06399328Recruiting

Cardiovascular Risk Stratification on the Basis of Surface Enhanced Raman Spectroscopy

Role: collaborator

NCT05115149Not ApplicableUnknown

The Study of a Neural Interface and a Neurostimulation in the Rehabilitation of Upper Limb Movement Impairments.

Role: collaborator

NCT04491240Phase 1Completed

Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.

Role: collaborator

NCT04602442Phase 2Unknown

Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia

Role: collaborator

All 5 trials loaded